# EDGAR Filing Document

**Accession Number:** 0001742692
**File Stem:** 0001178913-26-000869
**Filing Date:** 2026-3
**Character Count:** 7038
**Document Hash:** ab4deeb21533f7a1415c851f5ac5a1b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-000869.hdr.sgml**: 20260313

**ACCESSION NUMBER**: 0001178913-26-000869

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260313

**FILED AS OF DATE**: 20260313

**DATE AS OF CHANGE**: 20260313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMode Ltd.
- **CENTRAL INDEX KEY:** 0001742692
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39016
- **FILM NUMBER:** 26750044

**BUSINESS ADDRESS:**
- **STREET 1:** TAVOR BUILDING, SHA?AR YOKNEAM
- **STREET 2:** POB 533
- **CITY:** YOKNEAM
- **STATE:** L3
- **ZIP:** 2069200
- **BUSINESS PHONE:** 972-4-9097470

**MAIL ADDRESS:**
- **STREET 1:** TAVOR BUILDING, SHA?AR YOKNEAM
- **STREET 2:** POB 533
- **CITY:** YOKNEAM
- **STATE:** L3
- **ZIP:** 2069200

------

#### SECURITIES AND EXCHANGE COMMISSION <br> WASHINGTON, D.C. 20549

### FORM 6-K

#### REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16 OF<br> THE SECURITIES EXCHANGE ACT OF 1934

#### For the month of March 2026

#### <br>

### INMODE LTD.

#### <br>
(Exact name of registrant as specified in its charter)

#### Tavor Building, Sha'ar Yokneam

#### P.O. Box 533

#### Yokneam 2069206 Israel
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F ☒ Form 40-F ☐**

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

**Yes ☐ No ☒**

------

On March 13, 2026, InMode Ltd. (the "**Company**") announced that the Company's Board of Directors authorized the repurchase of up to 10% of the Company's outstanding ordinary shares, par value NIS 0.01 per ordinary share, in accordance with the terms of Rule 10b-18 promulgated under the Securities Exchange Act of 1934, as amended, from time to time in the open market or otherwise, in such quantities, at such prices, in such manner and on such terms and conditions as determined to be in the best interests of the Company, as disclosed in the press release.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br>

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| [99.1](exhibit_99-1.htm) | [Press Release dated March 13, 2026](exhibit_99-1.htm) |

---

------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **InMode Ltd.** |
|  | By: <u>/s/ Moshe Mizrahy</u> |
|  | Moshe Mizrahy |
| <br> March 13, 2026 | Chief Executive Officer |

---

------

## Exhibit 99.1

------

<u>**Exhibit 99.1**</u><br>

![](image00001.jpg)

#### InMode Announces New Share Repurchase Program
**YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD)**, a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares.

In 2025, the Company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs. Despite a challenging macroeconomic environment, the Company continues to generate strong cash flow and believes that repurchasing shares at its current valuation represents an attractive use of capital.

While management remains focused on navigating the ongoing regional conflict and maintaining a disciplined approach to capital allocation, the Company will continue to evaluate additional share repurchase programs and other capital allocation opportunities going forward.

The Company expects to fund repurchases under the program with available cash. Repurchases may be made from time to time in the open market or through other permitted means, subject to market conditions and applicable legal requirements. The program may be modified, suspended, or discontinued at any time at the Company's discretion.

#### About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit **<u>www.inmodemd.com/</u>**.

#### Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the actual amount of share repurchases made by the Company, if any. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2026, and our subsequent public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Company Contact: Yair Malca Chief Financial Officer Phone: (949) 305-0108 Email: <u>Yair.Malca@inmodemd.com</u> Investor Relations Contact Miri Segal MS-IR LLC Email: <u>ir@inmodemd.com</u>

------